208 results about "Myocardial tissue" patented technology

The invention discloses a preparation method and application of yak blood peptide with anti-hypoxia and anti-fatigue functions. The method comprises the steps of raw material pretreatment, composite enzymolysis (adopting a mixture of enzyme digestion modified lumbrukinase and nattokinase), enzyme deactivation, separation and purification, ferrous chelation, Maillard reaction, concentration and drying and the like. The enzymolysis efficiency and the active peptide yield are remarkably improved through ultrasonic treatment and a composite enzymolysis technology, the stability and the anti-hypoxia capacity of peptide fragments are enhanced through ferrous chelation, and the antioxidant activity and the anti-fatigue activity are further improved through the Maillard reaction. Experiments show that the yak blood peptide prepared by the method can significantly improve the antioxidant enzyme activity, prolong the normal-pressure hypoxia survival time, prolong the swimming exhaustion time and significantly reduce the MDA content of brain tissue and myocardial tissue. The obtained product can be applied to anti-hypoxia and anti-fatigue medicines or health-care foods, and has the advantages of high process efficiency, remarkable activity, high safety and the like.

The invention discloses a cardiac ultrasound image optimization enhancement method based on image filtering, and belongs to the technical field of cardiac ultrasound images. The invention discloses a cardiac ultrasound image optimization enhancement method based on image filtering. The method comprises the following steps: S1, obtaining a cardiac ultrasound binary image; s2, obtaining a to-be-processed cardiac ultrasound image; s3, highlighting the edge characteristics of the vascular wall and the myocardial tissue; s4, obtaining an enhanced cardiac ultrasound image; and S5, obtaining an optimized and enhanced cardiac ultrasound image. According to the method, the problem that the overall consistency judgment of structures such as heart chambers and valves is easily affected in the prior art is solved, the heart disease change area can be displayed more visually, misjudgment caused by noise or low contrast of medical staff is reduced, texture information of different levels can be effectively captured, the recognition capacity of a complex heart structure is enhanced, and the recognition efficiency is improved. Furthermore, the myocardial strain rate, the ventricular volume and other parameters are more accurately quantified, and a reliable basis is provided for evaluating the cardiac function.

The invention discloses an application of isorhamnetin in preparation of an anti-myocardial fibrosis medicine, and belongs to the technical field of medicines. The invention proposes that the isorhamnetin can effectively reduce myocardial tissue collagen deposition for the first time, and the medical application of the isorhamnetin is expanded. The isorhamnetin is used as the anti-myocardial fibrosis medicine, can effectively relieve the increase of mRNA expression levels of alpha-SMA, COL-1, COL-3, p53, PAI-1, IL-1beta and IL-6, and has the function of retarding myocardial fibrosis. The isorhamnetin is used as the active component of the anti-myocardial fibrosis medicine, the safety is high, the side effect is small, a novel anti-myocardial fibrosis treatment strategy is provided, and the application blank of the isorhamnetin in the field is filled.

The invention relates to a breast cancer chemotherapy myocardial stress quantitative evaluation method, which comprises the following steps of: acquiring an electromechanical response signal of a myocardial tissue of a chemotherapy patient in a pulsation period, extracting an electromechanical coupling delay parameter of a local tissue, and identifying an initial region of a chemotherapy-induced myocardial stress reaction; for the identified stress starting region and the adjacent cardiac muscle tissue, acquiring the transcellular membrane response time difference, and calculating a stress conduction lag difference index for characterizing the chemotherapy-induced asymmetric stress conduction characteristic; controllable micro-load intervention is carried out on a patient, and a strain reaction curve of a stress starting area and peripheral tissues after the load is applied is monitored; based on the response lag time, the strain peak change rate and the dynamic trend of recovering to the baseline in the load response process, the stress response elastic coefficient of the myocardial tissue is obtained through inversion and is used for quantifying the stress level of the myocardial after breast cancer chemotherapy; tiny changes of myocardial functions are quantified, and a trend judgment basis is provided.

The invention discloses injectable hydrogel with a myocardial tissue repairing function as well as a preparation method and application of the injectable hydrogel, and relates to the technical field of medical materials. The preparation method of the injectable hydrogel comprises the following steps: carrying out a reaction on deferoxamine and DSPE-PEG-NHS, so as to obtain DSPE-PEG-DFO; the preparation method comprises the following steps: wrapping carvedilol with DSPE-PEG-DFO under the hydrophilic and hydrophobic action, so as to obtain a drug-loaded nano-micelle; the preparation method comprises the following steps: reacting a polymer containing amino or hydroxyl with methacrylic anhydride to obtain a methylacryloyl modified polymer; reacting the carboxyl-containing polymer with cysteamine hydrochloride to obtain a sulfydryl modified polymer; mixing the drug-loaded nano-micelle, the methylacryloyl modified polymer and the sulfydryl modified polymer, and reacting under ultraviolet radiation to obtain the injectable hydrogel. The hydrogel disclosed by the invention is good in biocompatibility, can release deferoxamine and carvedilol in a ladder manner, is matched with a myocardial repair process, and realizes a function of repairing damaged myocardial tissues.

The invention belongs to the technical field of heart organ chips, and provides a heart organ chip optimization method based on mechanical matching, which is used for optimizing a double-layer substrate in a heart organ chip, a strain sensor and an electrophysiological electrode. A double-layer substrate in a heart organ chip, a strain sensor and an electrophysiological electrode are optimized, and the method comprises the steps that for the double-layer substrate simulating an extracellular matrix and an epicardium, the Young modulus is reduced by controlling phase change of tetradecane, introducing pores into polydimethylsiloxane and improving the cross-linking ratio of the polydimethylsiloxane; a strain sensor and an electrophysiological electrode based on carbon nanotube-polydimethylsiloxane are integrated into a double-layer substrate, and the Young modulus of the strain sensor and the Young modulus of the electrophysiological electrode are matched with the Young modulus of the double-layer substrate. The problem that the Young modulus of the substrate and the sensor material is too high is avoided, and mechanical matching among the soft myocardial tissue, the sensor and the substrate is achieved.

A delivery system and method are described that include a catheter and an active wire. The catheter has a catheter body that defines a primary lumen and a secondary lumen therethrough, which are spaced apart from each other. A distal end of the catheter body is configured to be located within a chamber of a heart proximate to myocardial tissue at a site of interest (SOI). The primary lumen has a greater cross-sectional size than the secondary lumen. The primary lumen is configured to receive at least a portion of an IMD therein and to permit the portion of the IMD to move relative to the catheter. The active wire is configured to extend through the secondary lumen so that a distal end of the active wire projects beyond the distal end of the catheter body to pierce the myocardial tissue at the SOI.

The application relates to a rotary cutting type myocardial biopsy forceps, which comprises a sleeve assembly, a catheter and a handle assembly, the distal end of the handle assembly is connected with the proximal end of the catheter, and the distal end of the catheter is connected with the sleeve assembly; the sleeve assembly comprises a sleeve body, the proximal end of the sleeve body is connected with the catheter, the distal end of the sleeve body is provided with an open port, the inside of the sleeve body is slidably provided with a rotary cutting knife, the inside of the catheter is provided with a first driving member, the handle assembly is drivingly connected with the rotary cutting knife through the first driving member, so as to drive the rotary cutting knife to extend out of the sleeve body and cut myocardial tissue; the distal end of the sleeve body is movably provided with a closing assembly, the inside of the catheter is provided with a second driving member, the handle assembly is drivingly connected with the closing assembly through the second driving member, so as to control the closing assembly to selectively open or close the open port at the distal end of the sleeve body. The rotary cutting type myocardial biopsy forceps can accurately control the sampling depth, and the open port at the distal end of the sleeve body can be closed after sampling, so that myocardial cells are prevented from falling off.

The rotary cutting type myocardial biopsy forceps comprise a sleeve assembly, a catheter and a handle assembly, the far end of the handle assembly is connected with the near end of the catheter, and the far end of the catheter is connected with the sleeve assembly; the sleeve assembly comprises a sleeve body, the near end of the sleeve body is connected with the catheter, the far end of the sleeve body is provided with an opening, a rotary cutter is slidably arranged in the sleeve body, a first driving part is arranged in the catheter, and the handle assembly is in driving connection with the rotary cutter through the first driving part and used for driving the rotary cutter to stretch out of the sleeve body. The cardiac muscle tissue is subjected to rotary cutting; a closing assembly is movably arranged at the far end of the sleeve body, a second driving part is arranged in the catheter, and the handle assembly is in driving connection with the closing assembly through the second driving part and used for controlling the closing assembly to selectively open or close an opening in the far end of the sleeve body. The rotary cutting type myocardial biopsy forceps can accurately control the sampling depth, and the opening in the far end of the sleeve body can be closed after sampling, so that myocardial cells are prevented from falling off.

The invention discloses a myocardial damage information analysis method and device based on multi-sequence magnetic resonance imaging, and the method comprises the steps: obtaining historical multi-sequence magnetic resonance imaging data generated by a myocardial tissue of a to-be-recognized object based on nuclear magnetic resonance, the historical multi-sequence magnetic resonance imaging data comprising an MTT sequence, a VNE image, a CEST sequence and an OS-BOLD sequence; inputting the historical multi-sequence magnetic resonance imaging data into a pre-trained myocardial injury information analysis model so as to analyze the historical multi-sequence magnetic resonance imaging data; and outputting multiple types of myocardial tissue regions corresponding to the historical multi-sequence magnetic resonance imaging data, and respectively calculating quantitative parameters of the MTT sequence, the VNE image, the CEST sequence and the OS-BOLD sequence in the multiple types of myocardial tissue regions to obtain myocardial damage information of the to-be-identified object. Therefore, by adopting the embodiment of the invention, the accuracy of the myocardial injury information is improved.

The invention provides a multi-mode ultrasonic monitoring method for degradation of a PFO degradable plugging device, and relates to the technical field of cardiovascular ultrasonic medical treatment. The multi-mode ultrasonic monitoring method for degradation of the PFO degradable occluder aims to overcome the technical defects that in the prior art, a single ultrasonic mode cannot achieve degradation progress quantification of the occluder, precise identification of residual shunt and evaluation of the integration degree of surrounding myocardial tissue at the same time. According to the method, three modalities of real-time three-dimensional transthoracic ultrasound (RT-3D TTE), ultrasonic contrast (CEUS) and shear wave elastography (SWE) are cooperatively applied, the form, hemodynamics and tissue elasticity data of the occluder are collected in stages, non-invasive, dynamic and accurate monitoring of the whole degradation process of the occluder is achieved in combination with preset quantitative indexes, and a reliable basis is provided for clinically adjusting a treatment scheme.

The invention relates to the technical field of medical image processing and three-dimensional reconstruction, and particularly discloses a reconstruction and analogue simulation method based on a cardiac image. The method comprises the following steps: firstly, preprocessing an input CT or MRI medical image, and automatically segmenting a heart multi-tissue structure by using an nnUNetv2 model, including a plurality of anatomical regions such as atrium, ventricle, myocardial tissue and blood pool; and then performing topology repair, smoothing processing and label resampling on the segmentation result to obtain a three-dimensional label body with a continuous structure and a complete boundary. And based on the optimized tag body, constructing a heart three-dimensional surface model by adopting a Marching Cubes algorithm, and generating a multi-material volume grid suitable for finite element analysis. According to an electrode position and a radio frequency parameter set by a user, a radio frequency ablation simulation model based on a Pennes biological heat conduction equation and an Arrhenius model is established, a temperature field and a tissue thermal damage range are calculated, and a simulation result is displayed in a three-dimensional mode in an overlapping mode. According to the method, the integrated process from medical image automatic segmentation to heart three-dimensional reconstruction and thermal simulation is realized, the segmentation precision, the modeling efficiency and the simulation reliability are improved, and the method can be applied to application scenes such as surgical planning, preoperative evaluation and medical teaching.

The invention relates to the technical field of model construction, in particular to a heart model construction method based on multiple physical fields and geometric multiple scales, which comprises the following steps of: performing segmentation processing and three-dimensional model reconstruction on a heart image to generate an initial heart geometric model; performing anisotropic attribute assignment on the initial heart geometric model based on a regularization algorithm to obtain a myocardial tissue structure; embedding a cell electrophysiological model into the computational grid of the myocardial tissue structure through parameter mapping to output a heart model with multi-scale geometric characteristics; an electrophysiological field equation, a mechanical field equation and a heart fluid dynamic field equation are constructed respectively, and coupling among multiple physical fields is achieved; determining whether the feature weight of the myocardial tissue structure texture needs to be increased or not; determining whether the transition function width of cell electrophysiological model parameter mapping needs to be increased or not; and determining a pressure feedback relaxation factor in the coupling iteration. The stability of heart model construction is improved.

The invention provides application of a CTSL inhibitor in preparation of a medicine for treating fulminant myocarditis, and particularly belongs to the technical field of biological medicine. It is found that CTSL in cardiac muscle tissue of a mouse with the fulminant myocarditis is remarkably increased, and the CTSL inhibitor can be used for preparing the medicine for treating the fulminant myocarditis. Results show that the CTSL inhibitor can improve myocardial cell injury, cardiac inflammation, rational reconstitution and functions of heart diseases, increase survival rate and realize treatment of fulminating myocarditis.

The present application relates to the technical field of model construction, and particularly relates to a heart model construction method based on multi-physical field and geometric multi-scale, comprising: carrying out segmentation processing and three-dimensional model reconstruction on a heart image to generate an initial heart geometric model, carrying out anisotropic attribute assignment on the initial heart geometric model based on a regularization algorithm to obtain a myocardial tissue structure; embedding a cell electrophysiology model into a calculation grid of the myocardial tissue structure through parameter mapping to output a heart model with multi-scale geometric characteristics; respectively constructing an electrophysiology field equation, a mechanics field equation and a heart fluid dynamics field equation to realize coupling between the multi-physical fields; determining whether the feature weight of the myocardial tissue structure texture needs to be increased; determining whether the transition function width of the cell electrophysiology model parameter mapping needs to be increased; and determining a pressure feedback relaxation factor in the coupling iteration. The present application improves the stability of heart model construction.

The device comprises an operating handle, an excision cavity with an opening in one side and a cutter, a freely-extending operating rod is arranged on the operating handle, the excision cavity is formed in the free end of the operating rod, and a suction limiting mechanism connected with external negative pressure suction equipment is movably arranged in an inner cavity of the excision cavity. The suction limiting mechanism is opposite to the opening of the excision cavity, can suck hypertrophic cardiac muscle tissue to be excided into the excision cavity, and can be close to or far away from the opening of the excision cavity so as to limit and adjust the depth of an inner cavity of the excision cavity, the cutter is movably arranged at the opening of the excision cavity in parallel, and a linkage mechanism is further arranged on the operating handle. The linkage mechanism penetrates through the operating rod to be connected with the cutter, the cutter can be pushed to move in parallel from one end of the opening of the excision cavity to the other end of the opening of the excision cavity so as to excide hypertrophic cardiac muscle tissue entering the excision cavity, by adjusting the position of the suction limiting mechanism, a doctor can conveniently control the excision thickness or depth, and the operation precision is improved.

The invention discloses a three-dimensional heart chip device. The device comprises a pneumatic control layer, a flexible functional film layer and a microfluidic culture layer, wherein the flexible functional film layer is integrated with a stretchable microelectrode array with a snakelike structure, and the microfluidic culture layer is arranged on the flexible functional film layer; wherein the pneumatic control layer is used for driving the flexible functional film layer to generate periodic deformation and applying mechanical tensile strain to cardiac muscle tissues in the microfluidic culture layer, and meanwhile, the stretchable microelectrode array of the snake-shaped structure synchronously deforms along with the flexible functional film layer and keeps conformal electric contact with the cardiac muscle tissues, so that the mechanical tensile strain is applied to the cardiac muscle tissues in the microfluidic culture layer. The electrophysiological signals are monitored in the dynamic mechanical stretching process. The technical problem that in the prior art, stable electrophysiological monitoring cannot be carried out while dynamic mechanical stretching is applied is solved, physiologically-related mechanical stimulation can be applied to three-dimensional cardiac muscle tissue to promote maturity of the three-dimensional cardiac muscle tissue, and long-term and stable in-situ electrophysiological signal monitoring is achieved in the process; and a more accurate in-vitro model is provided for drug screening and disease research.

To provide a system and method for generating, visualizing, and displaying cardiac signal information present at different depths in cardiac tissue. [Solution] Electroanatomical mapping of cardiac tissue is created at different depths using a multi-electrode catheter that collects electrical activity from within the patient's heart. Signal analysis of the electrical activity at a first location is performed based on the electrical activity received from multiple electrodes. The depth of the electrical activity at the first location is determined according to the signal analysis. This process is repeated at more than one depth for multiple further surface locations of the cardiac tissue. Multiple electroanatomical maps of the heart are generated, and the maps show the electrical activity at different depths of the cardiac tissue.

The invention relates to the field of biological medicine, in particular to a GDF-15 defect-based modeling method which comprises the following steps: ligating left coronary anterior descending branches of a plurality of GDF-15 knockout mice, and respectively establishing myocardial ischemia reperfusion models based on recombinant GDF-15 and normal saline; the method comprises the following steps: taking a myocardial tissue sample, and treating the sample at a pre-plating temperature and a pre-plating duration to obtain myocardial cells; detecting an AMPK signal channel expressed by the myocardial tissue protein; determining whether the activity of the AMPK signal path is inhibited or not based on the phosphorylation state value, and determining the osmotic pump rate; or, detecting the ROS level of the myocardial cells to obtain a captured image, determining the state of the myocardial cells based on the gray value of the image, and determining the stability of the state of the myocardial cells according to the oxidative stress index of the captured image; carrying out an anoxic experiment to obtain a fluorescence image; and determining the myocardial cell purity based on the fluorescence signal intensity, adjusting the osmotic pump rate, or adjusting the pre-plating time length or the pre-plating temperature, so that the accuracy of GDF-15 defect modeling drug administration is improved.

This invention belongs to the field of biomedical engineering technology, providing a method for preparing modular bio-ink for cell spheres and its application in the field of myocardial repair therapy. First, a method for preparing stem cell spheres based on microarrays is described. By introducing a protein / polyphenol composite coating onto the cell spheres, a multifunctional armor is created, providing immune protection and immunomodulatory therapy against the host's immune system to reverse the hostile microenvironment and promote the healing process of infarcted myocardial tissue. Second, using microfluidic droplet control technology, gel microspheres loaded with bioactive substances are prepared from biocompatible biomaterials. These microspheres are then densely packed and coated to form cell sphere particle gels. These gels can be used for disease treatment via direct injection or bio-3D printing, showing promising application prospects.

The invention discloses a mouse primary cardiac endothelial cell extraction method, and belongs to the technical field of biological cell extraction. The method comprises the following steps: step 1, obtaining pure myocardial tissues; 2, the treated heart tissue is transferred into an intelligent tissue grinding system to be ground; step 3, transferring the ground heart tissue into a temperature-controlled enzymolysis reactor, automatically monitoring the digestion process, and terminating the reaction when a preset digestion degree is reached; step 4, carrying out primary cell separation, carrying out magnetic separation by using anti-CD31 magnetic beads, and specifically enriching heart endothelial cells; 5, transferring the purified endothelial cells to an intelligent microenvironment culture system, and automatically optimizing a culture medium replacement period to adapt to a cell metabolism state; and step 6, performing multi-dimensional quality evaluation on the endothelial cells, wherein the multi-dimensional quality evaluation comprises marker expression analysis, in-vitro lumen formation experiment, AI-assisted morphological analysis and digital quality scoring.

The present invention generally relates to the field of recombinant gene expression in host cells. In particular, the invention relates to a recombinant human myeloid-derived growth factor (MYDGF) protein that exhibits a minimal degree of degradation upon expression in a host cell. The recombinant protein is therefore highly suitable for medical use, in particular for treating heart tissue damage and preventing cell death in myocardial tissue. The invention also provides a nucleic acid which encodes the recombinant protein and a host cell that expresses the recombinant protein. The invention also provides a method for producing the recombinant protein in a host cell.

The application discloses application of a reagent for detecting chemokine ligand 9 in preparation of a myocarditis early detection product. The application identifies immune cell characteristics in a mouse myocarditis early stage by using single cell RNA sequencing technology, and finds that compared with healthy mice, myocarditis mice have more macrophages infiltrating myocardial tissue and expressing chemokine ligand 9, which reveals that the chemokine ligand 9 can be used as a specific target for detecting acute myocarditis. Further, the application uses BPBBT, DSPE-mPEG 2000 and DSPE-PEG 2000 -MAL to prepare nanoparticles, designs a targeting peptide capable of specifically combining with the chemokine ligand 9 and connects the targeting peptide to a surface of the nano material, and thus myocarditis targeted nano probes are prepared. The myocarditis targeted nano probes can specifically gather in an inflammation area, and thus myocarditis can be accurately detected.

The invention is entitled "Breath control during cardiac ablation." The invention discloses a method for invasive cardiac treatment, the method comprising inserting a catheter into a beating heart of a patient who is anesthetically paralyzed and intubated for ventilation via a transvascular path, and temporarily stopping ventilation of the patient after the catheter is inserted. The method comprises moving the catheter between a plurality of locations of myocardial tissue of the heart with the ventilation stopped, and ablating the myocardial tissue of the heart at the plurality of locations with the ventilation stopped.

The invention belongs to the technical field of medical instruments, and particularly relates to an artificial mitral valve suture-free automatic implantation device which comprises a catheter, one end of the catheter is fixedly connected with an opening and closing puncture mechanism, the inner wall of the catheter is fixedly connected with a pushing mechanism, a groove is formed in the outer surface of the catheter, and a filling solvent bag is installed in the groove; through the arranged opening and closing puncture mechanism, the opening and closing puncture head enters the human body with the minimum incision and then is expanded after entering the human body, the initial puncture point is extremely small, direct injury to tissues such as blood vessels and cardiac muscle can be reduced, the path of the automatically expanded needle head is more regular, important blood vessels, nerves or cardiac muscle tissues can be avoided, the accidental injury risk is reduced, and the working efficiency is improved. According to traditional implantation, a puncture channel possibly needs to be expanded in advance, an open-close type needle head is automatically expanded after entering, an additional expansion step is not needed, traction and extrusion on surrounding tissue are reduced, and the possibility of hematoma and infection after an operation is reduced.

A delivery system and method are described that include a catheter (102) and a stylet (200). The catheter (102) defines a delivery lumen (146) therethrough. The stylet (200) extends through the delivery lumen (146) of the catheter (102) and is movable relative to the catheter (102). The stylet (200) includes a tip section (220) at a distal end (212) of the stylet (200). The tip section (220) selectively transitions between a narrow state and a flared state. The tip section (220) in the flared state has a greater lateral extension than the tip section (220) in the narrow state. The tip section (220) in the narrow state is configured to project beyond a distal end (116) of the catheter (102) to pierce cardiac tissue. The tip section (220) is configured to transition from the narrow state to the flared state to anchor the stylet (200) to the cardiac tissue.

This invention provides a traditional Chinese medicine compound for treating viral myocarditis, belonging to the field of traditional Chinese medicine pharmaceutical technology. The compound consists of Forsythia suspensa, Fagopyrum dibotrys, Pseudostellaria heterophylla, Rhodiola rosea, Citrus medica, Allium macrostemon, Poria cocos, Gynostemma pentaphyllum, Salvia miltiorrhiza, Dalbergia odorifera, Cynanchum paniculatum, and Valeriana. This traditional Chinese medicine compound exhibits significant protective effects against viral myocarditis, specifically by significantly reducing damage to H9c2 cardiomyocytes caused by CVB3 virus. Its mechanism of action is closely related to downregulating the expression of inflammatory factors TNF-α and IL-6 and inhibiting the inflammatory response. Simultaneously, within the experimental concentration range, the compound shows no toxicity to cardiomyocytes, demonstrating good biocompatibility. Furthermore, this compound can significantly reduce myocardial tissue damage in a viral myocarditis model mouse by inhibiting the in vivo inflammatory response and regulating oxidative stress imbalance, providing a safe and effective new treatment option for the clinical treatment of viral myocarditis.

The invention relates to an MOTS-c targeted delivery system based on an exosome derived from astragalus membranaceus and application of the MOTS-c targeted delivery system in myocardial ischemia-reperfusion injury. The preparation method comprises the following steps: preparing an exosome AExo from radix astragali from fresh radix astragali as a raw material, modifying a cardiac troponin I targeting peptide LPFFD to the surface of the AExo by using an EDC / NHS chemical cross-linking method to obtain LPFFD-AExo, and loading a mitochondrial derived small peptide MOTS-c into the LPFFD-AExo by using an ultrasonic-assisted penetration method to obtain the LPFFD-AExo-MOTS-c. According to the invention, the accurate delivery efficiency of the damaged myocardial tissue can be improved, and efficient and accurate delivery of MOTS-c to the ischemia reperfusion damaged myocardial tissue is realized, so that the ferroptosis inhibition capability of MOTS-c is obviously enhanced, the myocardial protection effect on MI / R injury is improved, and finally efficient targeted therapy on MI / R injury is realized.

A catheter system for use with a catheter with a distal assembly supporting a plurality of electrodes adapted to sense electrical signal in heart tissue and a force sensor configured to generate first contact signals representative of a contact force acting on the distal assembly. The system includes an ablation power generator configured to energize the plurality of electrodes, an impedance circuitry configured to generate second contact signals representative of the electrodes in contact with tissue, a processor configured to receive the first and second contact signals and generate switch signals in response thereto, and a switch circuitry configured to connect in response to the switch signals solely selected electrodes in contact with tissue to the ablation power generator in forming one or more composite electrodes.

The present invention provides the use of a PTMA protein coding sequence in the preparation of a drug for treating myocardial infarction. The PTMA protein coding sequence is a mouse PTMA protein coding sequence, a rat PTMA protein coding sequence, or a human PTMA protein coding sequence. The mouse sequence is shown in Seq ID No. 1, the rat sequence is shown in Seq ID No. 2, and the human sequence is shown in Seq ID No. 3. The PTMA protein coding sequence provided by the present invention can promote the proliferation of damaged myocardial cells, regenerate and repair myocardial tissue, reconstruct the heart morphology after myocardial infarction, restore the heart's pumping function, alleviate the development of cardiac pathological remodeling, prevent the occurrence of heart failure, and has a long-term therapeutic effect on cardiac function after myocardial infarction.